About Olaparib Side Effects
Olaparib is a prescription anticancer medicine that can cause side effects. Not every patient experiences the same effects, and the severity can vary depending on the individual, cancer type, treatment regimen, other medicines, and general health.
Some side effects are mild and manageable, while others can require medical assessment, treatment interruption, dose adjustment, or additional supportive care.
Patients taking Olanib 150 mg or Olakin 150 mg should follow the advice of their oncologist and report new, persistent, or concerning symptoms.
Common Side Effects of Olaparib
Commonly reported side effects may include:
- Nausea
- Vomiting
- Diarrhea
- Tiredness or weakness
- Headache
- Dizziness
- Decreased appetite
- Indigestion
- Changes in taste
- Cough
- Shortness of breath
- Anemia
- Decreased white blood-cell counts
- Decreased neutrophil counts
- Decreased platelet counts
The presence of a side effect does not necessarily mean that treatment must be stopped. Your healthcare professional can determine the appropriate way to manage it.
Nausea
Nausea is one of the commonly reported effects of olaparib.
It may occur after taking a dose and can sometimes affect appetite and daily activities.
Your doctor may recommend supportive measures or an anti-nausea medicine if appropriate.
If nausea is persistent or severe, tell your healthcare team.
Seek medical advice if nausea is accompanied by repeated vomiting, inability to keep fluids down, dizziness, or signs of dehydration.
Vomiting
Vomiting can occur during olaparib treatment.
Repeated vomiting may interfere with hydration and nutrition and may also affect your ability to take your prescribed medicines.
Contact your healthcare professional if vomiting is persistent or severe.
Do not automatically repeat an olaparib dose because you vomited unless your healthcare professional has specifically instructed you to do so.
Diarrhea
Diarrhea may occur during treatment.
Drink appropriate fluids to reduce the risk of dehydration unless your healthcare professional has advised you to restrict fluid intake.
Contact your healthcare team if diarrhea is severe, persistent, associated with weakness or dizziness, or accompanied by blood.
Tiredness and Weakness
Fatigue is a common experience among people receiving cancer treatment and can occur with olaparib.
Tiredness may range from mild to significant.
Try to balance activity with adequate rest and discuss persistent or worsening fatigue with your healthcare team.
Severe fatigue accompanied by breathlessness, paleness, dizziness, or rapid heartbeat may indicate anemia and should be assessed.
Headache
Headache can occur during olaparib treatment.
Mild headaches may be manageable with appropriate supportive measures.
If headaches become severe, persistent, unusual, or are accompanied by neurological symptoms, seek medical advice.
Do not routinely start pain medicines without considering your other medicines and medical conditions.
Dizziness
Some patients may experience dizziness.
If you feel dizzy:
- Sit or lie down until the sensation improves
- Stand up slowly
- Avoid activities that require full alertness if you are significantly affected
- Tell your healthcare professional if dizziness persists or becomes severe
Severe dizziness, fainting, chest symptoms, or significant weakness requires prompt medical assessment.
Decreased Appetite
Olaparib may reduce appetite in some patients.
Maintaining adequate nutrition is important during cancer treatment.
If you are eating significantly less than usual, losing weight unintentionally, or having difficulty maintaining adequate nutrition, inform your oncology team.
A dietitian or other healthcare professional may be able to provide additional nutritional support.
Indigestion
Indigestion or other gastrointestinal discomfort can occur during treatment.
Tell your healthcare professional if digestive symptoms are persistent, severe, or associated with vomiting, difficulty swallowing, significant abdominal pain, or unexplained weight loss.
Taste Changes
Some patients may experience changes in taste.
Food may taste different, less appealing, or unusually bitter or metallic.
Maintaining adequate food and fluid intake is important. If taste changes interfere substantially with nutrition, discuss them with your healthcare team.
Blood-Cell Changes
Olaparib can affect blood-cell production.
Possible laboratory abnormalities include reductions in:
- Hemoglobin
- Neutrophils
- White blood cells
- Platelets
These changes may not always cause obvious symptoms, which is why blood testing can be important during treatment.
Anemia
Anemia occurs when the body has fewer healthy red blood cells or insufficient hemoglobin.
Possible symptoms include:
- Tiredness
- Weakness
- Pale skin
- Shortness of breath
- Dizziness
- Reduced ability to perform normal activities
- Fast or noticeable heartbeat
Your doctor may monitor your blood counts regularly.
If anemia becomes significant, your healthcare team may investigate its cause and decide whether treatment modification or additional management is required.
Neutropenia and Other White-Blood-Cell Changes
Olaparib may reduce neutrophil or other white-blood-cell counts.
Because white blood cells help fight infections, significant reductions can increase infection risk.
Contact your healthcare team promptly if you develop a fever or other signs of infection.
Low Platelet Counts
A reduction in platelets can increase the tendency to bruise or bleed.
Possible warning signs include:
- Easy bruising
- Nosebleeds
- Bleeding gums
- Unusual or prolonged bleeding
- Small red or purple spots on the skin
Report unusual bleeding to your healthcare professional.
Severe or uncontrolled bleeding requires urgent medical attention.
Serious Side Effects
Although uncommon, olaparib can cause serious adverse reactions.
Important serious risks include:
- Myelodysplastic syndrome
- Acute myeloid leukemia
- Pneumonitis
- Severe blood-cell abnormalities
- Serious infection related to significant blood-count changes
- Serious pregnancy-related fetal harm
These risks should be discussed with your oncology team.
Myelodysplastic Syndrome and Acute Myeloid Leukemia
MDS and AML are rare but serious disorders involving abnormal blood-cell production.
Patients who have received previous chemotherapy or other cancer treatments may have additional risk factors.
Your healthcare professional may investigate persistent blood-count abnormalities when clinically appropriate.
Report persistent unexplained symptoms or abnormal blood-test results to your oncology team.
Pneumonitis
Pneumonitis is inflammation of the lungs and is a serious but uncommon adverse reaction associated with olaparib.
Possible symptoms include:
- New cough
- Shortness of breath
- Difficulty breathing
- Fever
- Other new respiratory symptoms
Do not ignore new or worsening breathing problems during treatment.
Prompt medical evaluation may be necessary to determine the cause and appropriate treatment.
Allergic or Hypersensitivity Reactions
Seek urgent medical attention if you develop symptoms suggesting a serious allergic reaction, such as:
- Difficulty breathing
- Swelling of the face, lips, tongue, or throat
- Severe rash
- Widespread skin reaction
- Fainting or severe weakness
Serious allergic reactions require immediate medical assessment.
When to Contact Your Doctor
Contact your healthcare professional if you experience:
- Persistent nausea or vomiting
- Significant diarrhea
- Severe tiredness
- Unexplained bruising
- Unusual bleeding
- Fever
- Recurrent infections
- Persistent cough
- New or worsening shortness of breath
- Significant dizziness
- Unexpected weight loss
- Any symptom that is new, severe, or worsening
Your doctor can determine whether the symptom is related to olaparib or another condition.
When to Seek Emergency Care
Seek urgent or emergency medical care for potentially life-threatening symptoms, including:
- Severe difficulty breathing
- Severe allergic reaction
- Uncontrolled bleeding
- Loss of consciousness
- Severe chest symptoms
- Severe weakness with other concerning symptoms
- A rapidly worsening medical condition
Do not wait for a routine appointment when symptoms appear severe or life-threatening.
Side Effects and Blood Tests
Some important effects of olaparib may first be detected through laboratory testing rather than symptoms.
For this reason, your healthcare professional may order regular blood tests.
Monitoring may include assessment of:
- Hemoglobin
- White blood-cell counts
- Neutrophils
- Platelets
- Other complete blood-count parameters
Additional tests may be recommended according to your health and treatment plan.
Managing Side Effects
Side-effect management should be individualized.
Depending on the type and severity of the reaction, your healthcare professional may recommend:
- Supportive medicines
- Dietary or hydration measures
- Additional laboratory testing
- Temporary treatment interruption
- Dose reduction
- Treatment discontinuation
- Investigation for another underlying cause
Never reduce or stop olaparib without discussing the decision with your treating healthcare professional, unless you are instructed to do so as part of urgent medical care.
Side Effects and Other Medicines
Some side effects can become more difficult to manage when olaparib is taken with other medicines.
Before using another prescription medicine, over-the-counter medicine, supplement, or herbal product, ask your doctor or pharmacist whether it is appropriate.
This is particularly important for medicines that can affect olaparib metabolism.
Side Effects During Combination Treatment
In some approved treatment settings, olaparib may be used together with another anticancer medicine.
When medicines are combined, side effects may come from one medicine, the other medicine, or both.
Your oncology team will consider the complete treatment regimen when evaluating symptoms and laboratory abnormalities.
Do not assume that every symptom is caused by olaparib.
Side Effects in Older Adults
Older adults may have other medical conditions or take several medicines at the same time.
This can affect how treatment is tolerated and may increase the importance of monitoring.
Tell your healthcare professional about all medicines and medical conditions before and during olaparib treatment.
Side Effects and Kidney Function
Reduced kidney function can increase exposure to olaparib.
Patients with impaired kidney function may therefore require a different dose depending on the degree of impairment and the applicable prescribing information.
If you develop a change in kidney function during treatment, your doctor may reassess your treatment.
Keep a Record of Concerning Symptoms
Keeping a simple record of symptoms can help your healthcare team evaluate treatment tolerability.
You may record:
- Date symptoms started
- Type of symptom
- Severity
- Duration
- Other medicines taken
- Food and fluid intake when relevant
- Temperature if fever is suspected
- Any changes in prescribed treatment
Bring relevant information to your oncology appointments.
Olanib 150 mg and Olakin 150 mg
The products featured on this website are:
Olanib 150 mg — Everest Pharmaceuticals Ltd.
Olakin 150 mg — Ziska Pharmaceuticals Limited
Both contain olaparib 150 mg as the active ingredient.
The side-effect profile can depend on the prescribed regimen, patient characteristics, other medicines, and the specific regulatory labeling applicable to the product.
Important Reminder
Not every patient will experience side effects.
Some patients may experience several adverse effects, while others may have few noticeable symptoms.
The absence of symptoms does not necessarily mean that monitoring can be skipped.
Continue required medical appointments and laboratory testing as recommended by your healthcare team.
Final Takeaway
Olaparib can cause common effects such as nausea, vomiting, diarrhea, tiredness, headache, decreased appetite, dizziness, and blood-count changes.
More serious adverse reactions, including MDS/AML and pneumonitis, are uncommon but important to recognize.
Report concerning symptoms promptly and seek emergency care for severe or life-threatening reactions.
Your oncologist should determine how side effects are managed and whether olaparib treatment should be continued, interrupted, adjusted, or discontinued.